Vancomycin Dosing and Monitoring 2 Years After the Guidelines

Ben M Lomaestro


Expert Rev Anti Infect Ther. 2011;9(6):657-667. 

In This Article

Five-year View

Increased use of rapid diagnostic techniques such as PCR may allow prompt discontinuation of vancomycin when not indicated. Further development of alternative antimicrobials may also lessen its use. If novel biomarkers and anti-oxidants provide improved monitoring or some protection against renal injury, more aggressive dosing might be more accepted. Clarification of differences between generic sources of the drug may also clarify potency and safety issues. Despite a mere 2 years since the vancomycin guidelines were first published, further data has questioned some of our long-held tenets of efficacy, toxicity and monitoring and directed areas for future research to optimize vancomycin usage while identifying risk factors for toxicity.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.